Clinical trials: Recurrence Hepatocellular Carcinoma, open to volunteers
Hepatocellular Carcinoma, Circulating Tumor Cell
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
On the basis of previous retrospective studies, the Task Force will further optimize the CTCs longitudinal surveillance model and initially validate the subclonal origin (CTC-DNA) of recurrent/metastatic foci derived from CTCs at…
- Conditions
- Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
- Trial name
- NCT06317896
- Testing
- circulating tumor cells
- Where
- 3 sites in China
- Volunteers
- 82 people
- Sponsor
- Zhujiang Hospital
Recurrent Liver Cancer, Primary Liver Cancer
Recurrent Liver Cancer: Reconceptualization and Reevaluation
The goal of this observational study is to determine if a specific protein can serve as a novel indicator for the recurrence of liver cancer.
- Trial name
- NCT06430983
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
Hepatocellular Carcinoma
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in…
- Trial name
- NCT05323201
- Testing
- fhB7H3.CAR-Ts, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
HCC
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC).
- Trial name
- NCT06420440
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Chen Xiaoping
Hepatocellular Carcinoma (HCC)
Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
Observational Model: Cohort Time Perspective: Other (prospective and retrospective data/sample collection) Primary Purpose: Other (biomarker validation for treatment response and recurrence prediction) Biospecimen Retention…
- Trial name
- NCT07840092
- Testing
- No investigational intervention. Participants receive standard clinical care. Clinical data, imaging/pathology information, and available biospecimens are collected for research.
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma (HCC)
Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection
This study tests whether it is safe and feasible to give patients with hepatocellular carcinoma (liver cancer) an infusion of their own (autologous) immune cells, called cytokine-induced killer (CIK) cells, after they have had…
- Trial name
- NCT07709299
- Testing
- Autologous Cytokine-Induced Killer (CIK) Cells
- Where
- Iran
- Volunteers
- 6 people
- Sponsor
- Royan Institute
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Scirrhous, Recurrence Tumor
HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma
Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative.
- Trial name
- HepatoPredict (NCT04499833)
- Testing
- liver transplant
- Where
- Portugal
- Volunteers
- 40 people
- Sponsor
- Centro Hospitalar de Lisboa Central
Hepatocellular Carcinoma
Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
Hepatocellular carcinoma (HCC) often has a poor prognosis after curative treatment due to frequent recurrence. Post-surgery, 60-70% of HCC patients experience recurrence, rising to 80% after ablation therapy.
- Trial name
- NCT06537193
- Testing
- AMRI, CT
- Where
- South Korea
- Volunteers
- 455 people
- Sponsor
- Asan Medical Center
HCC, Minimal Residual Disease
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Hepatocellular carcinoma (HCC) is a leading global cause of cancer-related mortality. While curative resection is pivotal, high postoperative recurrence rates remain a major challenge.
- Conditions
- HCC, Minimal Residual Disease, Recurrence
- Trial name
- NCT07350824
- Testing
- Adjuvant PD-1 inhibitors, Active monitoring
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tongji Hospital
Hepatecellular Carcinoma, Hepatectomy
AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery.
- Trial name
- NCT07062380
- Testing
- Curative liver resection, Real-world multimodal therapy
- Where
- China
- Volunteers
- 353 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
This study will evaluate nivolumab and ipilimumab, two immunotherapy medicines, given before repeat liver surgery in adults whose liver cancer (hepatocellular carcinoma) has returned within the liver after previous surgery.
- Trial name
- CA209-1594 (NCT07919717)
- Testing
- Nivolumab, Ipilimumab, Repeat Hepatectomy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
Solid Cancer, GPC3 Positive Hepatocellular Carcinoma
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have…
- Trial name
- NCT07242417
- Testing
- TC-G203 cells treatment
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing GoBroad Hospital
Hepatocellular Carcinoma
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
- Trial name
- NCT05489289
- Testing
- AK104
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Akeso
Recurrent Hepatocellular Carcinoma
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
This non-randomized phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab or Tislelizumab combined with Lenvatinib as neoadjuvant treatment for resectable RHCC patients
- Trial name
- TALENT (NCT04615143)
- Testing
- Tislelizumab, Tislelizumab combined with Levatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Carcinom, Hepatocellular
Adjuvant Everolimus in High-Risk Hepatocellular Carcinoma After Curative Resection (SEVERANCE Trial)
"Hepatic resection is the primary curative treatment for patients with a single, liver-confined hepatocellular carcinoma (HCC) without cirrhosis and is also considered in patients with cirrhosis if residual liver function is…
- Trial name
- NCT06972758
- Testing
- Certirobell®
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC)
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with…
- Conditions
- Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC)
- Trial name
- NCT07594964
- Testing
- XH001 Injection, mFOLFIRINOX Treatment Regimen
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Shenzhen Xinhe Biomedical
Hepatocellular Carcinoma (HCC)
AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
Hepatocellular carcinoma, the most common type of primary liver cancer, can recur after liver resection or thermal ablation performed with curative intent.
- Trial name
- HCC-AI-RECLAIM (NCT07732504)
- Testing
- Artificial Intelligence-Guided Risk-Adapted Surveillance, Fixed-Interval Surveillance
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer.
- Trial name
- REMNANT (NCT05375370)
- Testing
- circulating tumor DNA dosage
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Hepatocellular Carcinoma (HCC)
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
This is a prospective, observational, single-center study. The purpose of this study is to evaluate the efficacy of circulating tumor mitochondrial DNA (ct-mtDNA) in plasma as a biomarker for minimal residual disease (MRD)…
- Trial name
- CCGLC-015 (NCT06653062)
- Testing
- Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tongji Hospital